CYFRA 21-1: A potential molecular marker for noninvasive differential diagnosis of urothelial carcinoma of bladder

Biomarkers

Volumn 16, Issue 5, 2011, Pages 413-421

  Satyam, Abhigyan ^a   Singh, Prabhjot ^a   Sharma, Manoj ^b   Seth, Amlesh ^a   Sharma, Alpana ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Cytokeratins; Diagnostic biomarker; Early detection; Noninvasive diagnosis; Urinary bladder neoplasms; Urogenital cancer

Indexed keywords

CYTOKERATIN 19 FRAGMENT;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER DIAGNOSIS; CARCINOMA IN SITU; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINALYSIS; UROGENITAL TRACT CANCER;

ADULT; AGED; ANTIGENS, NEOPLASM; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KERATIN-19; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 79960762825     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.582152     Document Type: Article

References (39)

1. Andreadis C, Touloupidis S, Galaktidou G, Kortsaris AH, Boutis A, Mouratidou D. (2005). Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. J Urol 174:1771-5; discussion 1775. (Pubitemid 41546932)
2. Badjatia N, Satyam A, Singh P, Seth A, Sharma A. (2010). Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma. Urol Oncol 28:360-367.
3. Bjorklund B, Bjorklund V. (1957). Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique: Presence of an insoluble, heat-labile tumor antigen. Int Arch Allergy Appl Immunol 10:153-184.
4. Bodenmüller H. (1995). The biochemistry of CYFRA 21-1 and other cytokeratin-tests. Scand J Clin Lab Invest Suppl 221:60-66.
5. Chao D, Freedland SJ, Pantuck AJ, Zisman A, Belldegrun AS. (2001). Bladder cancer 2000: Molecular markers for the diagnosis of transitional cell carcinoma. Rev Urol 3:85-93.
6. Cooper D, Schermer A, Sun TT. (1985). Classifcation of human epithelia and their neoplasms using monoclonal antibodies to keratins: Strategies, applications, and limitations. Lab Invest 52:243-256. (Pubitemid 15144079)
7. Dittadi R, Barioli P, Gion M, Mione R, Barichello M, Capitanio G, Cocco G, Cazzolato G, De Biasi F, Praturlon S, Antinozzi R, Gianneo E. (1996). Standardization of assay for cytokeratin-related tumor marker CYFRA 21.1 in urine samples. Clin Chem 42:1634-1638. (Pubitemid 26354742)
8. Droller MJ. (1998). Bladder cancer: State-of-the-art care. CA Cancer J Clin 48:269-284. (Pubitemid 28428769)
9. Dyrskjøt L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, Kauppinen S, Ulhøi BP, Kjems J, Borre M, Orntoft TF. (2009). Genomic profling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 69:4851-4860.
10. Gadducci A, Ferdeghini M, Cosio S, Fanucchi A, Cristofani R, Genazzani AR. (2001). The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. Int J Gynecol Cancer 11:277-282. (Pubitemid 32751395)
11. Konety BR, Getzenberg RH. (2001). Urine based markers of urological malignancy. J Urol 165:600-611. (Pubitemid 32060487)
12. Lamm DL, Grifth JG. (1992). Intravesical therapy: Does it afect the natural history of superfcial bladder cancer? Semin Urol 10:39-44.
13. Lokeshwar VB, Obek C, Pham HT, Wei D, Young MJ, Duncan RC, Soloway MS, Block NL. (2000). Urinary hyaluronic acid and hyaluronidase: Markers for bladder cancer detection and evaluation of grade. j Urol 163:348-356.
14. MacVicar AD. (2000). Bladder cancer staging. BJU Int 86 Suppl 1:111-122.
15. Messing EM, Catalona W. (1998). Urothelial Tumors Of The Urinary Tract, In: Walsh PC, Retik AB, Vaughan ED, et al., eds. Campbell's Urology, 7th edn, vol 3. Philadelphia, WB Saunders Company, pp. 2329-2421.
16. Metts MC, Metts JC, Milito SJ, Tomas CR Jr. (2000). Bladder cancer: A review of diagnosis and management. J Natl Med Assoc 92:285-294.
17. Mian C, Lodde M, Haitel A, Vigl EE, Marberger M, Pycha A. (2000). Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder. Urology 55:223-226. (Pubitemid 30069920)
18. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. (1999). Immunocyt: A new tool for detecting transitional cell cancer of the urinary tract. J Urol 161:1486-1489. (Pubitemid 29420801)
19. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. (1982). The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 31:11-24. (Pubitemid 13215192)
20. Morsi MI, Youssef AI, Hassouna ME, El-Sedaf AS, Ghazal AA, Zaher ER. (2006). Telomerase activity, cytokeratin 20 and cytokeratin 19 in urine cells of bladder cancer patients. J Egypt Natl Canc Inst 18:82-92.
21. Nakata B, Chung YS, Kato Y, Ogawa M, Ogawa Y, Inui A, Maeda K, Sawada T, Sowa M. (1996). Clinical signifcance of serum CYFRA 21-1 in gastric cancer. Br J Cancer 73:1529-1532. (Pubitemid 26235378)
22. Nakata B, Ogawa Y, Ishikawa T, Ikeda K, Kato Y, Nishino H, Hirakawa K. (2000). Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 89:1285-1290.
23. Niklinski J, Furman M, Chyczewska E, Chyczewski L, Rogowski F, Laudanski J. (1995). Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer. Eur Respir J 8:291-294.
24. Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, Pode D. (2002). Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 94:2914-2922. (Pubitemid 34547690)
25. Pariente JL, Bordenave L, Jacob F, Gobinet A, Leger F, Ferriere JM, Le Guillou M. (2000). Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer. J Urol 163:1116- 1119. (Pubitemid 30169374)
26. Pariente JL, Bordenave L, Michel P, Latapie MJ, Ducassou D, Le Guillou M. (1997). Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol 158:338-341. (Pubitemid 27327662)
27. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, O'Kane DJ. (1999). Comparison of screening methods in the detection of bladder cancer. J Urol 161:388-394.
28. Sánchez-Carbayo M, Herrero E, Megías J, Mira A, Soria F. (1999). Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol 162:1951-1956.
29. Sánchez-Carbayo M, Urrutia M, González de Buitrago JM, Navajo JA. (2001). Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma. Cancer 92:2820-2828. (Pubitemid 33091918)
30. Sánchez-Carbayo M, Urrutia M, Silva JM, Romaní R, García J, Alférez F, González deBuitrago JM, Navajo JA. (2000). Urinary tissue polypeptide-specifc antigen for the diagnosis of bladder cancer. Urology 55:526-532. (Pubitemid 30157957)
31. Satyam A, Singh P, Badjatia N, Seth A, Sharma A. (2011). A disproportion of T1/T2 cytokines with predominance of T2, in urothelial carcinoma of bladder. Urol Oncol 29:58-65.
32. Schifer E, Vlahou A, Petrolekas A, Stravodimos K, Tauber R, Geschwend JE, Neuhaus J, Stolzenburg JU, Conaway MR, Mischak H, Teodorescu D. (2009). Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res 15:4935- 4943.
33. Southgate J, Harnden P, Trejdosiewicz LK. (1999). Cytokeratin expression patterns in normal and malignant urothelium: A review of the biological and diagnostic implications. Histol Histopathol 14:657-664. (Pubitemid 29159033)
34. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Fritsche HA, McDougal WS. (1998). Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 159:394-398. (Pubitemid 28049240)
35. Stieber P, Dienemann H, Hasholzner U, Fabricius PG, Schambeck C, Weinzierl M, Poley S, Samtleben W, Hofmann K, Meier W. (1994). Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int J Biol Markers 9:82-88. (Pubitemid 24225518)
36. Teyer G, Dürer A, Teyer U, Haberl I, Ulsperger E, Baumgartner G, Hamilton G. (1999). Measurements of free and total PSA, tissue polypeptide-specifc antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy. Prostate 41:71-77. (Pubitemid 29446961)
37. Wang R, Morris DS, Tomlins SA, Lonigro RJ, Tsodikov A, Mehra R, Giordano TJ, Kunju LP, Lee CT, Weizer AZ, Chinnaiyan AM. (2009). Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. Cancer Res 69:3810-3818.
38. Weber K, Osborn M, Moll R, Wiklund B, Lüning B. (1984). Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: Re-evaluation of a human tumor marker. Embo J 3:2707-2714.
39. Wild PJ, Fuchs T, Stoehr R, Zimmermann D, Frigerio S, Padberg B, Steiner I, Zwarthof EC, Burger M, Denzinger S, Hofstaedter F, Kristiansen G, Hermanns T, Seifert HH, Provenzano M, Sulser T, Roth V, Buhmann JM, Moch H, Hartmann A. (2009). Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. Cancer Epidemiol Biomarkers Prev 18:1798-1806.